Anvesana is leveraging RNAseq analysis platform to treat rare genetic disorders caused by gene dosage effects.

About

Anvesana is developing therapeutics to treat diseases caused by insufficient protein production. The core technology consists of an RNA-sequence analysis pipeline developed in the laboratory of Dr. Thomas Tuschl. Their platform can query mRNA sequence data to identify regions that can be targeted to up-regulate gene expression.